Teva Pharmaceutical Industries Ltd (XBUL:TEV)
лв 15.85 0 (0%) Market Cap: 17.96 Bil Enterprise Value: 48.53 Bil PE Ratio: 0 PB Ratio: 4.12 GF Score: 44/100

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 01:20PM GMT
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan. I'm very pleased to be hosting a fireside chat with Teva this morning. We have the Teva management team with us, and we're going to start with some opening comments from Teva's CEO, Kare Schultz, and we'll go into the Q&A.

So first of all, Kare and Eli, first, thanks for joining us, and happy new year to everybody.

Questions & Answers

Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

I just was -- thinking back to, I think, Kare, this is your third year presenting at the JPMorgan conference as CEO of Teva. I was really thinking back, and you've made a lot of progress repositioning the company during that time. So as we turn to 2021, hopefully, a more normalized year for everybody, would love to just hear your thoughts in terms of how you see Teva positioned today and your key priorities for the organization as we think about the company going forward.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot